You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Talimogene Laherparepvec (T-VEC)

Showing 1 - 25 of 8,048
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma Trial in Stanford, New York (Talimogene Laherparepvec (T-VEC),

Recruiting
  • Sarcoma
  • +2 more
  • Stanford, California
  • +1 more
Feb 2, 2023

Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma Trial in Zurich (Talimogene Laherparepvec (T-VEC))

Completed
  • Non-melanoma Skin Cancer
  • +4 more
  • Talimogene Laherparepvec (T-VEC)
  • Zurich, Switzerland
    Department of Dermatology, University Hospital Zurich
Mar 17, 2022

Angiosarcoma of Skin Trial in Tampa (T-VEC)

Active, not recruiting
  • Angiosarcoma of Skin
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Mar 22, 2022

Melanoma and Sarcoma Trial in London (Talimogene laherparepvec (T-VEC))

Completed
  • Melanoma and Sarcoma
  • Talimogene laherparepvec (T-VEC)
  • London, United Kingdom
    The Royal Marsden NHS Foundation Trust
Aug 17, 2021

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +13 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Breast Cancer Trial in Barcelona, Madrid, Valencia (Talimogene laherparepvec, Atezolizumab)

Active, not recruiting
  • Breast Cancer
  • Barcelona, Spain
  • +3 more
Sep 27, 2022

Melanoma, Merkel Cell Carcinoma, Other Solid Tumors Trial in Middletown, Harrison, New York (TALIMOGENE LAHERPAREPVEC (TVEC),

Active, not recruiting
  • Melanoma
  • +2 more
  • TALIMOGENE LAHERPAREPVEC (TVEC)
  • Hypofractionated Radiotherapy
  • Middletown, New Jersey
  • +2 more
Jul 13, 2022

Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be

Completed
  • Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected
  • Talimogene Laherparepvec
  • Chicago, Illinois
  • +2 more
Nov 17, 2022

Unresectable Stage IIIB-IV Malignant Melanoma Trial in Japan (Talimogene laherparepvec)

Completed
Has Results
  • Unresectable Stage IIIB-IV Malignant Melanoma
  • Talimogene laherparepvec
  • Nagoya-shi, Aichi, Japan
  • +8 more
Jan 13, 2023

Melanoma Trial in Brussels (CD1c (BDCA-1)+ myDC)

Active, not recruiting
  • Melanoma
  • CD1c (BDCA-1)+ myDC
  • Brussels, Belgium
    UZ Brussel
Dec 28, 2020

Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in

Active, not recruiting
  • Anatomic Stage 0 Breast Cancer AJCC v8
  • +21 more
  • Ipilimumab
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022

Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin Trial in Cincinnati (Talimogene laherparepvec (T-Vec), Dabrafenib

Withdrawn
  • Melanoma (Skin)
  • +4 more
  • Talimogene laherparepvec (T-Vec)
  • +2 more
  • Cincinnati, Ohio
    TriHealth Cancer Institute - Kenwood
Oct 14, 2020

Adenoid Cystic Skin Carcinoma, Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative Trial in United States

Recruiting
  • Adenoid Cystic Skin Carcinoma
  • +38 more
  • Biopsy
  • +6 more
  • Los Angeles, California
  • +35 more
Jan 31, 2023

Melanoma Trial in France, Germany, United States (Talimogene laherparepvec, Ipilimumab)

Completed
Has Results
  • Melanoma
  • Tucson, Arizona
  • +39 more
Mar 9, 2022

Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)

Terminated
Has Results
  • Melanoma
  • Talimogene Laherparepvec
  • +2 more
  • Birmingham, Alabama
  • +160 more
Nov 10, 2022

Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder

Withdrawn
  • Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
  • +3 more
  • Laboratory Biomarker Analysis
  • Talimogene Laherparepvec
  • San Francisco, California
    University of California, San Francisco
Jul 24, 2020

Advanced Non CNS Tumors Trial in Worldwide (Talimogene Laherparepvec)

Completed
  • Advanced Non CNS Tumors
  • Talimogene Laherparepvec
  • Wilmington, Delaware
  • +21 more
Dec 21, 2022

Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node Trial in Worldwide (Talimogene Laherparepvec,

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • +3 more
  • Scottsdale, Arizona
  • +31 more
Dec 7, 2022

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Trial in

Completed
  • Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
  • Information collection
  • Mobile, Alabama
  • +58 more
Sep 29, 2021

Solid Tumor Trial (BS006 Injection)

Not yet recruiting
  • Solid Tumor
  • BS006 Injection
  • (no location specified)
Jul 3, 2023

Solid Tumor Trial (OH2 Injection)

Not yet recruiting
  • Solid Tumor
  • OH2 Injection
  • (no location specified)
Jul 12, 2023

Melanoma Patients Treated With IMLYGIC® to Characterize Risk of

Recruiting
  • Melanoma
  • Herpetic Infection
    • Jefferson City, Missouri
    • +16 more
    Apr 11, 2022

    Unresected Stage IIIb to IVM1c Melanoma Trial in Worldwide (Talimogene Laherparepvec)

    Completed
    Has Results
    • Unresected Stage IIIb to IVM1c Melanoma
    • Talimogene Laherparepvec
    • Salt Lake City, Utah
    • +41 more
    Nov 26, 2021

    Solid Tumors, Mycosis Fungoides, Melanoma Trial in United States (TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 +

    Terminated
    • Solid Tumors
    • +7 more
    • TTI-621 Monotherapy
    • +4 more
    • Duarte, California
    • +6 more
    May 13, 2020

    Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Pexa-Vec)

    Active, not recruiting
    Has Results
    • Colorectal Cancer
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 24, 2023